

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): An RNA that demonstrates anti-HIV infection activity and is employed in prevention and treatment of AIDS, wherein said RNA is selected from the group consisting of:

~~a single stranded RNA comprising SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;~~

~~a single stranded RNA comprising a fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;~~

a double stranded RNA derived by annealing of SEQ ID NO:1 and the complementary sequence thereof, SEQ ID NO:2 and the complementary sequence thereof, or SEQ ID NO:3 and the complementary sequence thereof; and

a double stranded RNA derived by annealing of a fragment of SEQ ID NO:1 and the complementary sequence thereof, a fragment of SEQ ID NO:2 and the complementary sequence thereof, or a fragment of SEQ ID NO:3 and the complementary sequence thereof,

wherein said fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 is selected from the group consisting of

a 19 nt fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;

a 20 nt fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;

a 21 nt fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;

a 22 nt fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;

a 23 nt fragment of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3;

a 24 nt fragment of SEQ ID NO:2 or SEQ ID NO:3;

a 25 nt fragment of SEQ ID NO:2 or SEQ ID NO:3;

a 26 nt fragment of SEQ ID NO:2 or SEQ ID NO:3;

a 27 nt fragment of SEQ ID NO:3;

a 28 nt fragment of SEQ ID NO:3;

wherein said 19 nt fragment of SEQ ID NO:1 is selected from the group consisting of ucaaugaggaagcugcaga, caaugaggaagcugcagaa, aaugaggaagcugcagaau, augaggaagcugcagaug and ugaggaagcugcagaaugg; and

wherein said 19 nt fragment of SEQ ID NO:2 is selected from the group consisting of ggaagugacauagcaggaa, gaagugacauagcaggaaac, aagugacauagcaggaaacu, agugacauagcaggaaacu, gugacauagcaggaaacuac, ugacauagcaggaaacuacu, gacauagcaggaaacuacua and acauagcaggaaacuacuag.

2. (previously presented): The RNA of claim 1, wherein said RNA is modified at its 5' end or 3' end by adding two uracil nucleotides.

3. (previously presented): The RNA of claim 1, wherein said RNA is a Hairpin RNA consisting of a stem part and a loop part,

wherein said stem part is a double stranded RNA as claimed in claim 1, which is derived by annealing of

SEQ ID NO:1 and the complementary sequence thereof,

SEQ ID NO:2 and the complementary sequence thereof,

SEQ ID NO:3 and the complementary sequence thereof,

the fragment of SEQ ID NO:1 and the complementary sequence thereof,

the fragment of SEQ ID NO:2 and the complementary sequence thereof,
or the fragment of SEQ ID NO:3 and the complementary sequence thereof,
and wherein said loop is a non-complementary spacer.

4. (currently amended): A single-stranded or double-stranded DNA that demonstrates anti-HIV infection activity and is employed in prevention and treatment of AIDS, wherein:

1) said single-stranded DNA or one strand of said double-stranded DNA corresponds to the RNA of claim 1, or its complementary sequence; or

2) said single-stranded DNA or one strand of said double-stranded DNA corresponds to the RNA of claim 2, or its complementary sequence; or

3) said single-stranded DNA or one strand of said double-stranded DNA corresponds to the RNA ~~in accordance with~~ of claim 3, or its complementary sequence.

5. (previously presented): An expression vector that demonstrates anti-HIV infection activity and is employed in prevention and treatment of AIDS, wherein said vector contains any of the RNA of claims 1-3 or the DNA of claim 4.

6. (previously presented): A liposome that demonstrates anti-HIV infection activity and is employed in prevention and treatment of AIDS, wherein said liposome coats any of the RNA of claims 1-3, or the DNA of claim 4.

7. **(previously presented):** A method for the prevention or treatment of HIV infection or the prevention or treatment of AIDS, wherein RNA, DNA or fragments thereof according to any of Claims 1 to 4 are introduced into a eukaryotic cell line.

8. **(canceled).**

9. **(previously presented):** A liposome that demonstrates anti-HIV infection activity and is employed in prevention and treatment of AIDS, wherein said liposome coats the vector of Claim 5.

10. **(previously presented):** A method for the prevention or treatment of HIV infection or the prevention or treatment of AIDS, wherein expression vectors according to claim 5 are introduced into a eukaryotic cell line.

11. **(previously presented):** A method for the prevention or treatment of HIV infection or the prevention or treatment of AIDS, wherein liposomes according to claim 6 are introduced into a eukaryotic cell line.

12. **(previously presented):** A method for the prevention or treatment of HIV infection or the prevention or treatment of AIDS, wherein liposomes according to claim 9 are introduced into a eukaryotic cell line.